Published in Drug Law Weekly, March 16th, 2004
The issued claims are directed to vaccine compositions made up of epitopes from multiple HBV proteins, identified using Epimmune's proprietary epitope identification technology, designed to provide broader population coverage than prior vaccines.
Emile Loria, president and CEO of Epimmune said, "This is an important patent for the company coming shortly after our partner, Genencor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.